UBC researchers demonstrated in 2019 that pre-schoolers can safely overcome peanut allergies with a treatment called oral immunotherapy.
Now they have evidence that the earlier pre-schoolers start this treatment, the better.
This real-world study focused on infants younger than 12 months old and reveals that not only is oral immunotherapy effective against peanut allergies, it’s even safer for this age group than it is for toddlers and older pre-schoolers.
“This treatment is affordable, very safe and highly effective, particularly if we can get the treatment going before the infant is 12 months old,” said Dr. Edmond Chan, the study’s senior author who is also a clinical professor and head of allergy and immunology in UBC’s department of pediatrics at the BC Children’s Hospital Research Institute.
The study, recently published in the Journal of Allergy and Clinical Immunology: In Practice, looked specifically at outcomes for a group of 69 infants among a larger study group of 452 children aged five and under.
Oral immunotherapy is a treatment protocol in which a patient consumes small amounts of the allergenic food—in this case, peanut flour—with the dose gradually increased to a determined maximum amount. The aim is to desensitize the child until they can have a full serving of peanut protein without triggering a dangerous reaction. To sustain their immunity, the child must continue to eat peanut products on a regular basis long term.
For this study, children visited a pediatric allergist in a community or hospital clinic approximately every two weeks to receive their peanut dose. Parents gave the same daily dose at home between clinic visits. After eight to 11 clinic visits, the children had built up to a “maintenance dose” of 300 milligrams of peanut protein, or the equivalent of about 1.3 grams of peanuts.
Clinicians recorded any symptoms or reactions, and advised parents how to manage reactions at home.
Forty-two infants completed the build-up period plus one year of maintenance dosing. At the end of it, none of them had more than a mild reaction to a 4,000-gram dose of peanut protein, compared to 7.7 per cent of the children aged one to five who completed the protocol.
Seven infants dropped out along the way. Four experienced reactions beyond mild, but none required epinephrine injections. Another 20 did not have their peanut tolerance assessed at the end, either by choice or because of long wait lists.
Even before beginning the treatment, infants were shown to be at less risk than toddlers and pre-schoolers. In initial testing, only 33.9 per cent of infants had a reaction beyond mild, in comparison to 53.7 per cent of one-to-five year olds.
“Despite infants showing the best safety, we were still very satisfied with the safety of this treatment for older pre-schoolers. The risk of a severe reaction is much lower than it is for school-age kids,” Dr. Chan noted. “Many of the interventions we use in medicine, such as medications or surgical procedures, carry a small amount of risk that is outweighed by the benefit. If this treatment is performed by well-trained allergists and clinicians then I’m really comfortable with the risk. It’s actually very safe.”
As for effectiveness, the treatment worked equally well for both age groups. After a year of one peanut per day, approximately 80 per cent of the children had developed a tolerance for 4,000 milligrams of peanut protein in one sitting—the equivalent of roughly 15 whole peanuts.
The first step in trying to prevent peanut allergies among at-risk children is to introduce them to age-appropriate, peanut-containing foods such as peanut butter or peanut flour at around six months of age. If the infant still develops a peanut allergy, Dr. Chan’s research suggests that oral immunotherapy can be an effective alternative to avoiding allergens for a lifetime. Trying to avoid allergens altogether carries different risks, such as poor quality of life, social isolation and anxiety.
With this new data, the next step recommended by Dr. Chan’s team is for practitioners to offer oral immunotherapy as soon as possible after failed food allergy prevention during infancy, a concept that has recently been accepted for publication in a separate “Rostrum” article in the Journal of Allergy and Clinical Immunology: In Practice.
Dr. Chan has embraced oral immunotherapy in his own clinical practice. His research will help inform future clinical practice guidelines, and provide health professionals with the data they need to recommend it for their young patients as well.
Journal of Allergy and Clinical Immunology: In Practice
Method of Research
Subject of Research
Real-world peanut OIT in infants may be safer than non-infant preschool OIT and equally effective
Article Publication Date
L. Soller participates in research sponsored by DBV Technologies. S. Carr has received speaking honorarium from Aralez and Sanofi. S. Kapur has received a speaking honorarium from Pediapharm and has been a member of advisory boards for Bausch Health, Pediapharm, and Pfizer. M. McHenry has received a speaking honorarium from Merck and has been on an advisory committee for Novartis. V.E. Cook has been a member of advisory boards for Sanofi Genzyme, Bausch Health, and ALK, and has received speaking honoraria from Aralez Pharmaceuticals and CSL Behring. T. Wong has received speaking honoraria from Stallergenes Greer, Novartis, and Pfizer and is a subinvestigator in research sponsored by DBV Technologies. T.K. Vander Leek has served on advisory boards for Aralez and Pediapharm and has served on speaker bureaus for and received honoraria from Aralez, Pediapharm, and Pfizer. T.V. Gerstner has received a grant/research support from Merck and speaker honoraria from Pfizer and Mylan . J. Yeung has received unrestricted educational grants from Bausch Health , AstraZeneca , Stallergenes Greer, Novartis, Sanofi, Pediapharm, and Covis Pharma and has been on the following advisory committees: Pfizer, Health Link BC, Stallergenes Greer, Sanofi , and LEO Pharma. R. Mak has received speaker fees from Novartis , Pediapharm, and Astra Zeneca and advisory board honoraria for Sanofi. K.J. Hildebrand has received a speaker fee from Novartis, is a consultant to Health Link BC Allergy Nutrition services, and was paid travel expenses by AllerGenis as an allergy expert for the management of food allergy in a schools systematic review. S.B. Cameron has been a member of advisory boards for Bausch Health and Pfizer, and was a committee member of the Canadian Society of Allergy and Clinical Immunology oral immunotherapy guidelines. E.S. Chan has received research support from DBV Technologies, has been a member of advisory boards for Pfizer, Pediapharm, Leo Pharma, Kaleo, DBV, AllerGenis, Sanofi Genzyme, Bausch Health, and Avir Pharma, is a member of the health care advisory board for Food Allergy Canada, was an expert panel and coordinating committee member of the National Institute of Allergy and Infectious Diseases–sponsored Guidelines for Peanut Allergy Prevention, and is co-lead of the Canadian Society of Allergy and Clinical Immunology oral immunotherapy guidelines. The rest of the authors declare that they have no relevant conflicts of interest.